Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LiDer trial
2023-508583-30-00Phase 2Completed
- Sponsor
- Vall d'Hebron Institute of Oncology
- Start
- May 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lurbinectedin and dostarlimab in endometrial cancer (EC), sponsored by Vall d'Hebron Institute of Oncology. Primary endpoints: Maximum tolerated dose (MTD) of lurbinectedin + dostarlimab (Phase I), Recommended dose (RD) of lurbinectedin + dostarlimab (Phase I) and 1 more. Started May 2024; status: completed.
02
Drugs
lurbinectedindostarlimab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on 2023-508583-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508583-30-00.